Results 201 to 210 of about 375,044 (249)

T Cell Glycoengineering to Modulate Immune‐Tumor Crosstalk: A Universal Non‐Genetic Strategy for Enhanced Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study describes a T cell surface engineering strategy that integrates polymer materials with tumor immunology, aiming to achieve broad‐spectrum anti‐tumor applications of glycopolymer‐engineered T (G‐T) cells via non‐genetic modification. Glycopolymer engineering generally modulates immune‐tumor crosstalk through specific cell‐cell interactions ...
Lihua Yao   +8 more
wiley   +1 more source

Inhibition of Hypersialylation in Human Intervertebral Disc Degeneration Modulates Inflammation and Metabolism

open access: yesAdvanced Science, EarlyView.
Glycosylation, specifically hypersialylation, is identified as a critical factor in human intervertebral disc (IVD) degeneration—a major cause of low back pain. This study demonstrates that inhibiting sialylation reduces inflammation and oxidative stress in IVD tissues, suggesting new therapeutic possibilities.
Kieran Joyce   +8 more
wiley   +1 more source

Association between dietary carbohydrate intake and multiple sclerosis risk: a large-scale cohort study. [PDF]

open access: yesFront Nutr
Yuan Q   +11 more
europepmc   +1 more source

Nanoscale Mapping of the Subcellular Glycosylation Landscape

open access: yesAdvanced Science, EarlyView.
Using multiplexed super‐resolution imaging with fluorophore‐labeled lectins, this study reports intracellular glycosylation at the nanoscale across organelles and synaptic specializations. Extending glycan analysis beyond the cell surface, Glyco‐STORM reveals distinct glycosylation nanodomains in the ER, Golgi, lysosomes, and synaptic sites.
Helene Gregoria Schroeter   +4 more
wiley   +1 more source

Lactylated SPTAN1 Accelerates Hepatocellular Carcinoma Progression by Promoting NOTCH1/HES1 Activation and Immunosuppression

open access: yesAdvanced Science, EarlyView.
This study identifies SPTAN1‐kla as a novel oncogenic driver in HBV‐driven HCC, linking metabolic, epigenetic, and immune mechanisms. SPTAN1‐kla promotes HCC progression via NOTCH1/HES1 activation and immunosuppression. Findings highlight that targeting SPTAN1‐kla provides a framework for HCC treatment to improve clinical outcomes in HBV infected ...
Zengbin Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy